IGHV3-69-1
|
Chronic Lymphocytic Leukemia
|
0.100 |
AlteredExpression |
BEFREE |
Developmentally restricted immunoglobulin heavy chain variable region gene expressed at high frequency in chronic lymphocytic leukemia.
|
2503826 |
1989 |
IGHV3-69-1
|
Chronic Lymphocytic Leukemia
|
0.100 |
AlteredExpression |
BEFREE |
Thus, from our present observation of an albeit limited patient population, we have found an association between VH gene family use and CD5 antigen expression in chronic B-cell leukemias.
|
7513207 |
1994 |
IGHV3-69-1
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
Evidence for immunoglobulin heavy chain variable region gene replacement in a patient with B cell chronic lymphocytic leukemia.
|
8751479 |
1996 |
IGHV3-69-1
|
Chronic Lymphocytic Leukemia
|
0.100 |
AlteredExpression |
BEFREE |
Prior studies revealed that the leukemic B cells of patients with chronic lymphocytic leukemia (CLL) express a restricted Ig heavy chain variable region gene (VH gene) repertoire.
|
8977195 |
1997 |
IGHV3-69-1
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
To clarify the cellular origin of de novo CD5+ diffuse large B-cell lymphoma (CD5+ DLBL), particularly in comparison with other CD5+ B-cell neoplasms such as chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), we analyzed the nucleotide sequence of the Ig heavy chain variable region (IgVH) genes of de novo CD5+ DLBL cases.
|
9454743 |
1998 |
IGHV3-69-1
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
Here we demonstrate that some cases of B-CLL involved in lymph node carried mutated VH genes and showed intraclonal diversity like the tumor cells in the peripheral blood.
|
11699415 |
2001 |
IGHV3-69-1
|
Chronic Lymphocytic Leukemia
|
0.100 |
AlteredExpression |
BEFREE |
This study evaluates the prognostic significance of genetic abnormalities (detected at or shortly after presentation), clinical stage, lymphocyte morphology, CD38 expression, and IGVH gene status in 205 patients with chronic lymphocytic leukemia (B-CLL).
|
12149195 |
2002 |
IGHV3-69-1
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
The immunoglobulin variable heavy chain (IgVH) gene mutation status is an important prognostic factor in chronic lymphocytic leukemia (CLL), since cases with mutated VH genes show significantly longer survival than unmutated cases.
|
12586612 |
2003 |
IGHV3-69-1
|
Chronic Lymphocytic Leukemia
|
0.100 |
Biomarker |
BEFREE |
The mutational status of immunoglobulin heavy-chain variable-region (IgVH) genes in the leukemic cells of chronic lymphocytic leukemia (CLL) is an important prognostic factor in the disease.
|
12724482 |
2003 |
IGHV3-69-1
|
Chronic Lymphocytic Leukemia
|
0.100 |
AlteredExpression |
BEFREE |
In five of the six unmutated CLLs, the DLBL clones evolved from CLL tumorclones and the VH genes expressed by DLBLs were also unmutated.
|
14671632 |
2004 |
IGHV3-69-1
|
Chronic Lymphocytic Leukemia
|
0.100 |
AlteredExpression |
BEFREE |
We developed a flow cytometry assay for ZAP-70 protein expression and investigated its concordance with ZAP-70 mRNA expression, IgVH gene mutational status, and clinical outcome in 167 patients with CLL.
|
14726163 |
2004 |
IGHV3-69-1
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
In B-cell chronic lymphocytic leukemia (B-CLL), somatic mutation of IgVH genes defines a subgroup with favorable prognosis, whereas the absence of IgVH mutations is correlated with a worse outcome.
|
14961033 |
2004 |
IGHV3-69-1
|
Chronic Lymphocytic Leukemia
|
0.100 |
Biomarker |
BEFREE |
High expression of activation-induced cytidine deaminase (AID) mRNA is associated with unmutated IGVH gene status and unfavourable cytogenetic aberrations in patients with chronic lymphocytic leukaemia.
|
14961036 |
2004 |
IGHV3-69-1
|
Chronic Lymphocytic Leukemia
|
0.100 |
Biomarker |
BEFREE |
We examined the immunoglobulin (Ig) heavy chain variable region genes (V(H) genes) used by leukemia cells of 1220 unrelated patients with chronic lymphocytic leukemia (CLL).
|
15217828 |
2004 |
IGHV3-69-1
|
Chronic Lymphocytic Leukemia
|
0.100 |
AlteredExpression |
BEFREE |
Although the presence of an unmutated IgV(H) gene is strongly associated with the expression of ZAP-70, ZAP-70 is a stronger predictor of the need for treatment in B-cell CLL.
|
15329427 |
2004 |
IGHV3-69-1
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
Geographic patterns and pathogenetic implications of IGHV gene usage in chronic lymphocytic leukemia: the lesson of the IGHV3-21 gene.
|
15466924 |
2005 |
IGHV3-69-1
|
Chronic Lymphocytic Leukemia
|
0.100 |
Biomarker |
BEFREE |
Chronic lymphocytic leukemia (CLL) is a clonal B-cell disorder, which has recently been divided into 2 subtypes based on the somatic hypermutation status of the immunoglobulin heavy chain (IgVH) genes.
|
15621758 |
2004 |
IGHV3-69-1
|
Chronic Lymphocytic Leukemia
|
0.100 |
Biomarker |
BEFREE |
Fluorescent-labeled DNA probes were used to study 52 chronic lymphocytic leukemia (B-CLL) patients for (1) disease progression, (2) angiogenesis genes, (3) T-cell leukemia 1 gene (TCL1), (4) immunoglobulin heavy chain variable region (IGHv) and (5) chromosome 6q.
|
15661260 |
2005 |
IGHV3-69-1
|
Chronic Lymphocytic Leukemia
|
0.100 |
Biomarker |
BEFREE |
Novel data on the pathogenesis and concepts of cell origin in CLL are also reviewed stressing the fact that there is biased IgVH gene usage, and the importance of mutational status of the CLL cell, as reported in recent years by different authors.
|
15737877 |
2005 |
IGHV3-69-1
|
Chronic Lymphocytic Leukemia
|
0.100 |
PosttranslationalModification |
BEFREE |
We have evaluated the rate of response to fludarabine as first-line therapy in 54 patients with advanced stage CLL, analysing the cytogenetic profile, aberrations in p53, including the methylation status of its promoter, and the immunoglobulin heavy-chain variable-region (IGVH) mutation status.
|
15801955 |
2005 |
IGHV3-69-1
|
Chronic Lymphocytic Leukemia
|
0.100 |
Biomarker |
BEFREE |
To assess the prognostic value of these genes, we quantified their expression by real-time quantitative polymerase chain reaction (PCR) in a cohort of 127 patients with CLL and correlated this with clinical outcome, IGVH mutational status, and ZAP-70 protein expression.
|
15802535 |
2005 |
IGHV3-69-1
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation |
BEFREE |
The methods identified 144 genes that were differentially expressed between cases of CLL with unmutated compared with mutated Ig VH genes.
|
16049305 |
2005 |
IGHV3-69-1
|
Chronic Lymphocytic Leukemia
|
0.100 |
Biomarker |
BEFREE |
The existence of subsets that comprise given IGKV-J/IGLV-J domains associated with IGHV-D-J domains that display homologous CDR3 provides further evidence for the role of antigen in CLL pathogenesis.
|
16076869 |
2005 |
IGHV3-69-1
|
Chronic Lymphocytic Leukemia
|
0.100 |
AlteredExpression |
BEFREE |
Measuring ZAP-70 methylation status at C-334 is a simple and reproducible method for predicting prognosis in CLL, which is closely associated with ZAP-70 expression and IgVH gene mutational status.
|
16079107 |
2005 |
IGHV3-69-1
|
Chronic Lymphocytic Leukemia
|
0.100 |
AlteredExpression |
BEFREE |
A unique microRNA expression signature composed of 13 genes (of 190 analyzed) differentiated cases of CLL with low levels of ZAP-70 expression from those with high levels and cases with unmutated IgV(H) from those with mutated IgV(H) .
|
16251535 |
2005 |